MDT-AP-1349
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 33.839999999999996
- os_event
- true
- age_years
- 4
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.607828279
- umap2_2d
- -7.326735665
- umap1_3d
- -3.879057638
- umap2_3d
- -2.939959093
- umap3_3d
- 5.996438245
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.510
- MITOTIC_SPINDLE+0.450
- E2F_TARGETS+0.370
- INTERFERON_ALPHA_RESPONSE+0.340
- NOTCH_SIGNALING+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- ALLOGRAFT_REJECTION+0.250
- APICAL_SURFACE+0.240
- INTERFERON_GAMMA_RESPONSE+0.230
- HEDGEHOG_SIGNALING+0.210
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.470
- ADIPOGENESIS-0.310
- HEME_METABOLISM-0.250
- FATTY_ACID_METABOLISM-0.220
- DNA_REPAIR-0.200
- XENOBIOTIC_METABOLISM-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
- P53_PATHWAY-0.150
- UV_RESPONSE_UP-0.150
- PANCREAS_BETA_CELLS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934821 | — | — | 0.780 |
| 2 | MDT-AP-0704 | Med | Medulloblastoma | 0.765 |
| 3 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.764 |
| 4 | TCGA-34-5239-01A-21R-1820-07 | — | cohortSQ1 | 0.764 |
| 5 | TCGA-98-8023-01A-11R-2247-07 | — | cohortSQ1 | 0.758 |
| 6 | TCGA-37-A5EM-01A-21R-A27Q-07 | — | cohortSQ1 | 0.751 |
| 7 | MDT-AP-2863 | Med | Medulloblastoma | 0.750 |
| 8 | SRR934755 | — | — | 0.748 |
| 9 | SRR10899983 | — | — | 0.739 |
| 10 | SRR8613802 | — | D | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |